Immunotherapy: 424 Real Stories

424 stories match immunotherapy. 352 of them mention chemotherapy.

A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Metastatic lung adenocarcinoma causing sudden hearing loss and vertigo

Patient Info: Anonymized, Female, 60s | Stage IV

Metastatic Site: bone|liver|brain|internal auditory meatus

About 10 months after the metastatic diagnosis, she developed new left-sided deafness, vertigo and facial weakness associated with metastatic involvement of the internal auditory meatus.

PubMed Central
OutcomeSetback / Progression
Dianne, who was diagnosed with Stage III Ovarian CancerOvarian Cancer

Stage III Ovarian Cancer: Dianne's Patient Story

Patient Info: Dianne Simpson, female, 70+ | Stage III

Dianne completed treatment in April 2017 after chemotherapy, hysterectomy and a pembrolizumab clinical trial and was looking ahead to survivorship.

MD Anderson
OutcomeNot reported
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Finding Happiness Despite Stage IV Lung Cancer

Patient Info: Anonymized, 50s | Stage IV

More than a year after diagnosis, she remained in treatment for Stage IV lung cancer, with some therapies losing effectiveness as the cancer developed resistance.

Dana-Farber
OutcomeLiving With Cancer
Marianne, who was diagnosed with Breast CancerBreast Cancer

Breast Cancer: Marianne's Survivor Story

Patient Info: Marianne Gongos, Female, 60s

Marianne had been breast cancer-free since June 13, 2013. Her separate chronic myeloid leukemia was also in remission after she restarted its medication.

Cleveland Clinic
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV ERBB2-Mutated Lung Adenocarcinoma With Brain Metastases and Multiple Targeted Therapies

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: ERBB2 exon 20 insertion, exact sequence not specified. ERBB2 copy-number gain was identified during progression on afatinib.

Metastatic Site: brain, adrenal gland, liver

The final documented afatinib plus bevacizumab rechallenge produced a mixed response followed by liver progression after 3 months.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Lung Cancer Immunotherapy Caused New Type 1 Diabetes

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: No ALK, ROS1, KRAS or EGFR alteration was detected; CK7-positive; TTF-1-negative; PAX-negative; CK20-negative

Metastatic Site: Pleura

After 4 combination-treatment cycles, the right-lung nodules had decreased markedly and nearly resolved. He continued maintenance pembrolizumab every 3 weeks and remained on insulin with stable glucose control.

PubMed Central
OutcomeLiving With Cancer / Ongoing Therapy
Bill, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV Lung Cancer: Bill's Patient Story

Patient Info: Bill Smith, Male | Stage IV

Biomarkers: Genomic testing performed; specific result not reported

Metastatic Site: Brain; liver; bone/humerus

As of October 2016, Bill was receiving immunotherapy every 2 weeks, all tumors had shrunk, chemotherapy had stopped and he reported markedly improved quality of life while living with Stage IV lung cancer.

Cleveland Clinic
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV ER/PR-positive mucinous breast cancer: long-term no evidence of disease after surgery, AFTV, radiation, CEF, and endocrine therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive; PR-positive; delayed-type hypersensitivity to AFTV became pseudo-positive after vaccination and remained pseudo-positive 5.4 years later

Metastatic Site: Th7 vertebra

More than 6 years after primary surgery, she remained well with no evidence of vertebral metastasis activity, new metastasis, or local recurrence.

PubMed Central
OutcomeCancer-Free / NED